Skip to main content

Table 1 Hormonal and adipose tissue measurements by DXA in the two women with acromegaly.

From: Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series

Parameters Normal range Patient Phase 1a Phase 2b
Serum IGF-1 (ng/mL) 94 to 267
(60.8 to 297.7)c
Patient 1 264 252
  20 to 182
(34.5 to 219)c
Patient 2 162.0 94
Serum IGFBP-3 (ng/mL) 3400 to 6900 Patient 1 5670 5550
   Patient 2 4737 3623
Body weight (kg) - Patient 1 79.0 81.5
   Patient 2 58.3 59.5
Abdominal fat on DXA (g) - Patient 1 11555 10033
   Patient 2 14200 13133
Percentage of abdominal fat on DXA (%) - Patient 1 32.3 31.6
   Patient 2 43.9 43.1
Thigh fat on DXA (g) - Patient 1 8344 9032
   Patient 2 7883 9692
Percentage of thigh fat on DXA (%) - Patient 1 32 33
   Patient 2 43.7 47.5
Total body fat on DEXA (g) - Patient 1 25285 27450
   Patient 2 27321 29212
Percentage of total body fat on DEXA (%) - Patient 1 34.7 36.9
   Patient 2 44.4 46.8
Total fat free mass on DEXA (g) - Patient 1 47590 47000
   Patient 2 34190 33149
Percentage of total fat free mass on DEXA (%) - Patient 1 65.3 63.1
   Patient 2 55.6 53.2
  1. aPegvisomant (10 mg/day) administered by subcutaneous injection into the abdomen; bpegvisomant (10 mg/day) administered by subcutaneous injection into the thighs; cage-related ranges from the Laboratory of Modena and the Italian population.